Research chemicalResearch chemicalDissociativeArylcyclohexylamine

3-Cl-PCP

Also known as 3-chloro-PCP · 3-Cl-PCP

Written by enwyReviewed 4 Aug 20261 sources0 comments

3-Cl-PCP (3-chlorophencyclidine) is a chlorinated analogue of PCP that appeared on the research-chemical market in the 2010s. It is an NMDA receptor antagonist reported to be potent and long-acting, with essentially no formal human data. User reports and its structural relationship to PCP point to comparatively high toxicity and agitation risk.

01 Overview

3-Cl-PCP is one of the more recent PCP analogues to reach grey-market distribution. It has not been studied clinically, and knowledge of its effects rests on anecdote and analogy to PCP.

Reported effects include strong dissociation, stimulation and analgesia, with a notably long duration that encourages inadvertent redosing. Like PCP, it appears to carry a higher risk of agitation, psychosis and general toxicity than the diarylethylamine dissociatives, and its potency makes accurate dosing difficult.

02 Mechanism

Non-competitive NMDA receptor antagonist (open-channel blocker); chlorination is thought to increase potency and duration relative to PCP.

03 Dosing

Tier	Dose	Route	Notes
Light (uncertain)	2–5 mg	Insufflated	Poorly characterised; caution due to potency.
Common (uncertain)	3–8 mg	Oral	Estimated; potent and long-acting, high redosing risk.

04 Effects

Effect	Magnitude	Evidence
DissociationStrong detachment, depersonalisation and derealisation.		Anecdotal
StimulationEnergising effect reported at lower doses.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Agitation and psychosisParanoia, agitation and dissociative psychosis; toxicity reported higher than diarylethylamine dissociatives.	Severe	Elevated vs newer dissociatives	Unconfirmed
Ataxia and anaesthesiaLoss of coordination progressing to dissociative anaesthesia with fall and injury risk.	Moderate	Dose-dependent	Anecdotal
Prolonged toxicity from redosingLong, ill-defined duration makes cumulative overdose likely if redosed.	Severe	With redosing	Unconfirmed

06 Legal status

United States

Possibly controlled as a PCP analogue (Analogue Act)

as of Jan 2026

United Kingdom

Class A (PCP analogue)

as of Jan 2026

07 References

PCP analogues as novel psychoactive substancesPubMed search

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.